NASD · Healthcare · Biotechnology · USA
Cardio Diagnostics Holdings Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.
Cardio Diagnostics Holdings develops epigenetics-based clinical blood tests for cardiovascular disease assessment and detection using its AI-driven Multi-Omics Engine. The company offers Epi+Gen CHD for coronary heart disease risk evaluation and PrecisionCHD for disease detection. Its customers include healthcare providers, employers, payors, and health systems.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Cardio Diagnostics Holdings Inc stock.
Fairly valued: intrinsic value $1.73 per share, market price $1.71, margin of safety 1.3% (as of 2026-11-17).
Its liquidation floor, current assets minus every liability, values the shares at $1.73; the price of $1.71 is 1% below that value.
21 more in this industry show a wider margin of safety.
CDIO is fairly valued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $1.73; the price of $1.71 is 1% below that value.
$1.73 per share (as of the 2026-11-17 close), against a market price of $1.71. That is a margin of safety of 1.3%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.